The PURE COVID-19, a sub-study of PURE, is a unique opportunity to document factors that predispose people to SARS-CoV-2 infection in different populations across high, middle and low-income countries.
The sub-study’s objectives are to:
PURE COVID-19 can be conducted with a high level of speed and efficiency by leveraging the PURE study, in which 200,000 people have been recruited in more than 1000 communities in 27 countries. Participants have already been characterized in detail prior to 2019. Data were collected on socio-economic factors, living circumstances, cooking fuels (solid versus gas or electricity), diet, social isolation, depression, alcohol and tobacco use, morbidities, physical activity, medications, anthropometrics, blood pressure and handgrip strength. Lung function was measured by spirometry. Also, blood specimens were stored in a central biobank.
In the PURE COVID-19 sub-study, we propose to draw a blood sample from 40,000 people from PURE countries and communities with high infection rates according to local reports. In this way, we will serologically identify participants who have been infected by SARS-CoV-2 (symptomatic and asymptomatic). Data collected during follow-up include vital status, incident heart failure, chronic lung disease, pneumonia, myocardial infarction, stroke and hospitalization. Anthropometrics, blood pressure, handgrip strength and lung function are being re-measured. Follow-up is planned for at least a further 3 years.
We will compare participants with serologic evidence of SARS-CoV-2 exposure (cases) with participants without exposure (controls) stratified by community to identify independent risk factors for SARS-CoV-2 infection. We will assess differences between SARS-CoV-2 cases and controls with respect to change in forced expiratory volume in 1 second (FEV1) and forced vital capacity between baseline and follow-up by using linear mixed effects models to identify possible effects of SARS-CoV-2 infection on lung function.ESC 2021 Presentation - DOWNLOAD PDF
2020 - 2022
Darryl Leong is a Scientist at PHRI, Director of the McMaster University and Hamilton Health Sciences Cardio-Oncology Program, Associate Professor, Department of Medicine (Cardiology), McMaster University, and Staff Cardiologist at Hamilton Health Sciences. He has methodological expertise in clinical epidemiology and clinical trials, and content expertise in physical frailty, echocardiography, and cardio-oncology. His research is supported by the CIHR, and he has published more than 150 manuscripts including all the leading internal medical and cardiovascular journals.
He graduated from the University of Adelaide Medical School with Deans Listing and Honours for academic excellence, completed his cardiology training, Doctor of Philosophy, Master of Public Health, and Master of Biostatistics degrees at the University of Adelaide in Australia, and completed a post-doctorate fellowship in cardiovascular imaging at the Leiden University Medical Centre in The Netherlands, before re-locating to Canada.
Sumathy Rangarajan has been Program Director, Global Health, since 2016, preceded by many years’ service at PHRI in other roles. She oversees the PURE study team, as well as the INVICTUS rheumatic AF treatment trial, the CANPWR pediatric weight management registry, and others.
She holds both a Bachelor of Science Degree and a Master of Science degree from Pune University in India.
Maha Mushtaha has been employed by the Population Health Research Institute since 2011, working currently in the global health research group on the following studies: PURE, SCHOLAR-2 and TIMING. She has experience with site and database management of large, international observational studies as well as investigator-initiated clinical trials.
She holds a Bachelor of Science Degree from McMaster University and a Biotechnology Diploma from Mohawk College.
Back To Top